NEWS

New Trial Alert: Alliance A212102 MCED Biobank Study

August 1, 2022

Alliance A212102: Blinded Reference Set for Multicancer Early Detection Blood Tests

Overview: Alliance investigator Marie E. Wood, MD (University of Colorado) leads this study that collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the labora


New Trial Alert: Alliance A032101 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A-DREAM

July 15, 2022

Alliance A032101: A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (mHSPC): A-DREAM

Overview: Atish Choudhury, MD, PhD, of the Dana-Farber Cancer Institute, leads this phase II trial that examines antiandrogen therapy interruptions in patients with hormone-sensitive prostate can


Alliance A021501 Trial Establishes FOLFIRINOX as Preferred Treatment Regimen

July 14, 2022

In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX plus hypofractionated radiotherapy, according to research from The University of Texas MD Anderson Cancer Center published today in JAMA Oncology.

The multicenter, randomized p


Older News